Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Oculomotor apraxia
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
Deglutition Disorders
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Dysarthria
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Nystagmus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Gait, Unsteady
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Absent reflex
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Cerebellar Dysmetria
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Dysdiadochokinesis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Romberg's sign positive
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Oculovestibuloauditory syndrome
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hypermetric saccades
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Distal muscle weakness
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Cerebellar atrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Ataxia, Appendicular
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Sensorimotor neuropathy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Distal sensory impairment
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Nystagmus, CTCAE 3.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Nystagmus, CTCAE 5.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Hormone refractory prostate cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
513 patients with castrate-resistant prostate cancer (CRPC), including 284 patients who received radiotherapy, 229 patients without radiotherapy and 152 healthy individuals were genotyped for five polymorphisms in DNA excision repair genes:ERCC1 N118N (500C>T), XPD K751Q (2282A>C), XRCC1 R194W (685C>T), XRCC1 R399Q (1301G>A) and PARP1 V762A(2446T>C).
|
20495366 |
2010 |
Lung Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Lung tumors from 204 smokers with non-small cell lung cancer (NSCLC) were analyzed for mutations in exons 5-8 of the p53 gene and genotypes of XPD and XRCC1. p53 mutations were found in 20% (40/204) of the patients.
|
12844488 |
2003 |
Bladder Neoplasm
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case-control study.
|
18365755 |
2008 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer risk associated with individual SNPs was seen for GSTP1 [A allele; odds ratio (OR) = 1.85; 95% confidence interval (CI), 1.04-3.27] and XRCC1 (A/A genotype; OR = 1.68; 95% CI, 1.01-2.79) in white women and CYP1B1 (G allele; OR = 11.1; 95% CI, 1.18-104) in black women smokers.
|
19174490 |
2009 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer risk associated with individual SNPs was seen for GSTP1 [A allele; odds ratio (OR) = 1.85; 95% confidence interval (CI), 1.04-3.27] and XRCC1 (A/A genotype; OR = 1.68; 95% CI, 1.01-2.79) in white women and CYP1B1 (G allele; OR = 11.1; 95% CI, 1.18-104) in black women smokers.
|
19174490 |
2009 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer risk associated with individual SNPs was seen for GSTP1 [A allele; odds ratio (OR) = 1.85; 95% confidence interval (CI), 1.04-3.27] and XRCC1 (A/A genotype; OR = 1.68; 95% CI, 1.01-2.79) in white women and CYP1B1 (G allele; OR = 11.1; 95% CI, 1.18-104) in black women smokers.
|
19174490 |
2009 |